<div><b>Conflict of interest statement</b></div><div>The author has no conflict of interest to declare.</div><div>References</div><ol><li>Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxiamine: a
review of its mechanism of action and its role in COVID-19.<i>Frontiers Pharmacol</i> . 2021; 12:652688. Doi:
10.3389/fphar.2021.652688</li><li>Dodds MG, Doyle EB, Reiersen AM, Brown F, Rayner CR. Fluvoxamine for
the treatment of COVID-19. <i>Lancet Glob Health</i> . 2022;
10(3):e332. Doi: 10.1016/S2214-109X(22)00006-7.</li><li>Lee TC, Vigod S, Bortolussi-COurval E, Hanula R, Boulware DR, Lenze
EJ, Reiersen AM, McDonald EG. Fluvoxamine for outpatient management of
COVID-19 to prevent hospitalization. A systematic review and
meta-analysis. <i>JAMA Network Open.</i> 2022; 5(4):e226269.
Doi:10.1001/jamanetworkopen.2022.6269</li><li>Guo CM, Harari O, Chernecki C, THorlund K, Forrest JI. Fluvoxamine for
the early treatment of COVID-19: a meta-analysis of randomized
clinical trials. <i>Am J Trop Med Hyg</i> . 2022; 106(5):1315-1320.</li><li>Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE,
Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs
placebo and clinical deterioration in outpatients with symptomatic
COVID-19. <i>JAMA</i> . 2020; 324(22):2292-2300.</li><li>Lenze E. Fluvoxamine for early treatment of COVID-19: a fully-remote,
randomized placebo controlled trial. <i>ClinicalTrials.gov</i> .
Accessed May 26, 2022.
https://clinicaltrials.gov/ct2/show/NCT04668950</li><li>Reis G, dos Santos Moreira-Silva EA, Medeiros Silva DC, Thabane L,
Cruz Milagres A, Santiago Ferreira T, Quirino dos Santos CV et al.
Effect of early treatment with fluvoxamine on risk of emergeny care
and hospitalizations among patients with COVID-19: the TOGETHER
randomized platform trial. <i>Lancet Glob Health</i> . 2022; 10:
e42-51.</li><li>Seo H, Kim H, Bae S, Park S, Chung H, Sung H, Jung J et al.
Fluvoxamine treatment of patients with symptomatic COVID-19 in a
community treatment center: a preliminary result of randomized
controlled trial. <i>Infect Chemother</i> . 2022; 54(1):102-113.</li><li>Langan D, Higgins JPT, Jakson D, Bowden J. Veroniki AA, Kontopantelis
E, Viechtbauer W, Simmonds M. A comparison of heterogeneity variance
estimators in simulated random-effects meta-analyses. <i>Res Synth
Methods</i> . 2019; 10(1):83-98.</li><li>Röver C. Bayesian random-effects meta-analysis using the bayesmeta R
Package. <i>J Stat Softw</i> . 2020;1(6). doi:10. 18637/jss.v093.i06</li><li>Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with
R: a practical tutorial. <i>Evid Based Ment Health</i> . 2019;
22(4):153-160.</li></ol>